Table 8 ASSURE patient plasma: apabetalone reduces circulating TNFα targets that correlate with CVD risk in patient plasma
VI process | TNFα target | Protein symbol | Apabetalone versus placebo | |
|---|---|---|---|---|
% change | p value | |||
Plaque stability | Stromelysin-1 | MMP-3 | − 26.8 | 0.005 |
Plaque stability | Macrophage metalloelastase | MMP-12 | − 24.6 | 0.003 |
Inflammatory mediator Plaque stability | Fractalkine | CX3CL1 | − 22.0 | 0.0003 |
Inflammatory mediator Plaque stability | C-reactive protein | CRP | − 21.3 | 0.02 |
Inflammatory mediator Plaque stability | Pappalysin-1 | PAPPA | − 14.6 | 0.02 |
Inflammatory mediator Plaque stability | Osteoprotegerin | TNFRSF11B | − 14.0 | 0.003 |
Inflammatory mediator Plaque stability | Periostin | POSTN | − 13.3 | 0.01 |
Inflammatory mediator | Oncostatin-M | OSM | − 13.1 | 0.01 |
Atherogenesis Adhesion | Vascular cell adhesion protein 1 | VCAM1 | − 12.2 | 0.005 |
Inflammatory mediator | Toll-like receptor 4:Lymphocyte antigen 96 complex | TLR4 LY96 | − 11.2 | 0.03 |
Inflammatory mediator | Serum amyloid P-component | APCS | − 10.8 | 0.001 |
Inflammatory mediator Plaque stability | Angiopoietin-2 | ANGPT2 | − 10.2 | 0.01 |